Ignite Creation Date:
2024-05-06 @ 3:21 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02262975
Status:
COMPLETED
Last Update Posted:
2016-12-28
First Post:
2014-08-26
Brief Title:
A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimers Disease Patients Who Have Been Newly Prescribed With Donepezil Aricept in Asia ADOS
Sponsor:
Eisai Korea Inc
Organization:
Eisai Inc
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ADOS
Brief Summary:
This study is an observational study conducted prospectively under routine clinical setting for 1 year with about 700 patients diagnosed as Alzheimers disease who will be treated by donepezil Aricept as monotherapy The subjects will be recruited in the selected institutions of about 8 countries in Asia
Detailed Description:
Participation in this study places no additional visit schedule which will be determined by the investigators judgment based on the disease progression of each subject Investigators educate subjects to keep decided visit schedule and collect the required information for case record from CRF on the visit
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None